Alprazolam

PTSD — alprazolam may worsen symptoms; this concern is specific to alprazolam among benzodiazepinessupported

Unique alprazolam findings: worsening PTSD. pmid:8262890

Claim in safety — inconclusiveinconclusiveworking →

Alprazolam-related deaths increased by 233.8% between 2003 and 2009 in the United States, and benzodiazepines were involved in a 5-fold increase in overdose deaths from 1999 to 2009supported

5-fold increase in BZD deaths 1999-2009. Alprazolam showed 233.8% increase in death rates 2003-2009. 0897190013515001

A case report documented fatal oxymorphone-alprazolam polydrug overdose with blood alprazolam of only 0.04 mg/L — below the therapeutic range — demonstrating that pharmacodynamic synergism can be lethal even at subtherapeutic benzodiazepine concentrationssupported

Oxymorphone+alprazolam combination overdose death. Blood alprazolam 0.04 mg/L (below therapeutic range). Alprazolam synergism contributed to fatal respiratory depression. pmid:21819798

A separate case documented fatal posthypoxic leukoencephalopathy following benzodiazepine-induced hypoxic coma.supported

Fatal leukoencephalopathy following hypoxic coma induced by benzodiazepine overdose. s12883-015-0320-6

GABA-A receptor downregulation underlies tolerance, while cognitive impairment — particularly memory deficits — does not fully tolerate with chronic use, with residual deficits documented after discontinuationsupported

43 long-term BZD users (avg 5 years): tolerance to psychomotor impairment but NOT to short-term memory impairment or reduced CFF. pmid:2871579

Long-term benzodiazepine use is associated with risk of cognitive decline and potential dementia in prospective epidemiological studies, and chronic use may diminish hippocampal volume and impair neuroplasticity.supported

Prospective epidemiological studies examining BZD use and risk of incident cognitive decline. Major public health issue regarding long-term BZD-induced cognitive deficits persisting after withdrawal. pmid:15841867

Long-term benzodiazepine use is associated with risk of cognitive decline and potential dementia in prospective epidemiological studies, and chronic use may diminish hippocampal volume and impair neuroplasticity.supported

Chronic BZD use may diminish hippocampal volume, impair neuroplasticity, and heighten dementia risk. s11033-026-11660-x

PTSD worsening: Alprazolam may exacerbate PTSD symptoms — a concern not reported with the same frequency for other benzodiazepinessupported

Unique alprazolam findings: worsening PTSD, increased impulsivity in borderline personality disorder, mania/hypomania. pmid:8262890

Impulsivity in borderline personality disorder: Increased impulsive behavior in patients with borderline personality disorder has been reported specifically with alprazolamsupported

Unique alprazolam findings: worsening PTSD, increased impulsivity in borderline personality disorder, mania/hypomania. pmid:8262890

Mania or hypomania: More commonly reported with alprazolam than with older benzodiazepines, representing a risk for patients with bipolar spectrum disorderssupported

Unique alprazolam findings: worsening PTSD, increased impulsivity in borderline personality disorder, mania/hypomania. Older BZDs more commonly reported for other events. pmid:8262890

At 0.5 mg, acute administration produces large effects on visual attention (Cohen's d = 0.8); at 1.0 mg, additional impairment of working memory and learning emergessupported

0.5 mg: large effect on visual attention (d=0.8). 1 mg: psychomotor + moderate working memory and learning impairment. pmid:15912482

Chronic low-dose use (0.5 mg/day for 2 weeks) produces statistically significant visual memory impairment without affecting attention or psychomotor performance.supported

0.5 mg/day for 2 weeks impaired visual memory on PAL and DMS tests. Psychomotor performance unaffected. 3730940

Tolerance develops selectively: psychomotor impairment and sedation tolerate, but short-term memory impairment persists with chronic usesupported

tolerance to psychomotor impairment but NOT to short-term memory impairment or reduced CFF. pmid:2871579

The mechanism involves a multi-level cascade: GABA-A receptor downregulation, transcriptional repression of the α1 subunit via L-type calcium channel signaling, epigenetic modification via HDAC1/2 upregulation, and clathrin-mediated receptor internalizationpartially supported

BZD agonists produced tolerance associated with GABA-A receptor downregulation… Gene expression for GABA-A subunits changed with chronic lorazepam. pmid:1652596

A fatal polydrug overdose has been documented with blood alprazolam at only 0.04 mg/L — below the therapeutic range.supported

Oxymorphone+alprazolam combination overdose death. Blood alprazolam 0.04 mg/L (below therapeutic range). pmid:21819798

The mechanism involves a multi-level cascade: GABA-A receptor downregulation, transcriptional repression of the α1 subunit via L-type calcium channel signaling, epigenetic modification via HDAC1/2 upregulation, and clathrin-mediated receptor internalizationsupported

Diazepam exposure induces uncoupling of GABA/BZD sites and transcriptional downregulation of alpha1 GABA-A subunit via L-type calcium channels. j.neulet.2020.134801

The mechanism involves a multi-level cascade: GABA-A receptor downregulation, transcriptional repression of the α1 subunit via L-type calcium channel signaling, epigenetic modification via HDAC1/2 upregulation, and clathrin-mediated receptor internalizationsupported

10-14 days diazepam treatment increased HDAC1 and HDAC2 in frontal cortex. prp2.416

The mechanism involves a multi-level cascade: GABA-A receptor downregulation, transcriptional repression of the α1 subunit via L-type calcium channel signaling, epigenetic modification via HDAC1/2 upregulation, and clathrin-mediated receptor internalizationsupported

GABA-A receptors sequestered into clathrin-coated vesicles increased 83%; synaptic membrane Bmax decreased 33%. pmid:9336347

The α5 subtype plays a critical role in sedative tolerance development, and GABA-A receptor subtypes make distinct contributions to both tolerance and dependence.supported

Alpha5-knock-in mice failed to develop sedative tolerance to diazepam. Alpha5 downregulation in dentate gyrus associated with tolerance manifestation. pmid:15282283

The α5 subtype plays a critical role in sedative tolerance development, and GABA-A receptor subtypes make distinct contributions to both tolerance and dependence.supported

Subtype-specific contributions to tolerance and dependence confirmed. j.drugalcdep.2021.108985

Precipitated withdrawal was confirmed in squirrel monkeys after only 9 days of daily administration, producing tremor, vomiting, and convulsionspartially supported

After 18 days oral alprazolam in monkeys, flumazenil-precipitated withdrawal (tremor, vomiting, convulsions) occurred in all treated animals. pmid:7617819

Withdrawal is characterized by CRF mRNA upregulation exceeding 300% within 24–48 hours of discontinuation in dependent animals, driving HPA axis activation, anxiety rebound, tremor, insomnia, and — in severe cases — seizuressupported

Withdrawal produced CRF mRNA expression >300% increase in cerebral cortex, peaking 24-48h. Also HPA axis activation and suppression of food intake. pmid:15496666

One-third of panic disorder patients receiving long-term alprazolam could not discontinue during a 3-week taper.supported

One-third could not discontinue during 3-week taper. pmid:9872708

Chlordiazepoxide substitution at approximately 86:1 ratio (chlordiazepoxide mg to alprazolam mg), followed by 10%/day taper over 7–14 days, has demonstrated efficacy in case seriessupported

Mean substitution ratio 86:1 (chlordiazepoxide:alprazolam mg). 7-14 day taper at 10%/day. No seizures. pmid:7966502

CBT augmentation significantly improves discontinuation success rates.supported

Adjunctive CBT provided significant benefit over taper alone at 6-month follow-up (large effect sizes). j.brat.2010.04.002

This is the principal cause of alprazolam-related fatalitysupported

Pharmacodynamic synergism produces respiratory depression with opioids. 0897190013515001

Claim in safety — inconclusiveinconclusiveworking →

Claim in safety — inconclusiveinconclusiveworking →

Azole antifungals (itraconazole, ketoconazole) produce a confirmed 2-fold AUC increasesupported

Itraconazole pretreatment caused 2-fold AUC increase for alprazolam. acs.molpharmaceut.7b00006

Azole antifungals (itraconazole, ketoconazole) produce a confirmed 2-fold AUC increasepartially supported

Ketoconazole and itraconazole are potent CYP3A4 inhibitors. Coadministration with CYP3A substrates including alprazolam can result in clinically significant drug interactions. pmid:10709776

Claim in safety — inconclusiveinconclusiveworking →

Claim in safety — inconclusiveinconclusiveworking →

Macrolide antibiotics (clarithromycin, erythromycin), HIV protease inhibitors (ritonavir), nefazodone, and grapefruit juice all inhibit CYP3A4 with risk of excessive sedationsupported

Clinically important CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, erythromycin, nefazodone, ritonavir, grapefruit juice) can cause excessive sedation when coadministered with alprazolam. pmid:10668858

Claim in safety — inconclusiveinconclusiveworking →

Rifampin decreases alprazolam AUC by 72–91%, risking subtherapeutic levels and, in dependent patients, precipitated withdrawal.supported

Rifampin pretreatment caused 72-91% decrease in alprazolam AUC. acs.molpharmaceut.7b00006

Claim in safety — inconclusiveinconclusiveworking →

No clinically significant pharmacokinetic interactions have been documented with propranolol, metronidazole, disulfiram, oral contraceptives, ethanol (pharmacokinetically), or alosetronsupported

mean alprazolam AUC 210 and 202 ng.h/mL without and with alosetron. No significant pharmacokinetic interaction - safe to coadminister. pmid:11304902

Claim in safety — inconclusiveinconclusiveworking →

Claim in safety — inconclusiveinconclusiveworking →

In opioid-dependent populations, alprazolam attenuates morphine withdrawal severity via locus coeruleus noradrenergic suppression, which may contribute to the high prevalence of benzodiazepine-opioid co-use.supported

Alprazolam reduced affective and physical components of naloxone-precipitated opioid withdrawal in rats. Prevented naloxone-induced hippocampal noradrenaline increase via locus coeruleus dampening. pmid:8905331

Borderline personality disorder — risk of increased impulsive behaviorsupported

Unique alprazolam findings: …increased impulsivity in borderline personality disorder. pmid:8262890

Bipolar spectrum disorders — risk of mania or hypomania inductionsupported

Unique alprazolam findings: …mania/hypomania. pmid:8262890

Severe hepatic disease — clearance markedly reduced, requiring substantial dose adjustment or avoidancesupported

Reduced clearance in elderly and cirrhosis. pmid:8513649

Elderly — reduced clearance even in apparently healthy individuals; increased fall risksupported

Reduced clearance in elderly and cirrhosis. pmid:8513649

Concurrent opioid use — pharmacodynamic synergism producing respiratory failure; FDA black box warning appliessupported

Pharmacodynamic synergism produces respiratory depression with opioids. 0897190013515001

Pharmacokinetics are dose-independent (linear), with proportional increases in AUC and Cmax confirmed across the 2–10 mg sustained-release dose range.supported

AUC and Cmax increased proportionally with dose (linear PK). pmid:9115058

Optimal anxiolytic and antipanic efficacy corresponds to steady-state plasma concentrations of 20–40 µg/Lsupported

Optimal panic disorder plasma concentrations 20-40 mcg/L. pmid:8513649

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

The IV-versus-oral crossover study (n=6 healthy volunteers) established a mean fractional absorption of 0.92supported

6 fasting male subjects received oral and IV 1.0-mg doses… Mean fraction absorbed (oral) = 0.92. pmid:6152055

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

Alprazolam crosses the blood-brain barrier readily; PET studies using [¹¹C]alprazolam confirmed brain uptake at approximately 1% of the administered dosesupported

PET studies in 6 normal subjects. Brain uptake ~1% administered dose. pmid:7550022

Both metabolites appear in plasma at less than 10% of parent drug concentrations across all tested dosespartially supported

Metabolites alpha-OH and 4-OH alprazolam <15% of parent concentration at all doses. pmid:9115058

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

Elderly: Clearance significantly reduced even in apparently healthy elderly individuals — dose reduction indicatedsupported

Reduced clearance in elderly and cirrhosis. pmid:8513649

Hepatic impairment: Clearance markedly reduced in cirrhosis — dose reduction essentialsupported

Reduced clearance in elderly and cirrhosis. pmid:8513649

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

The CRF upregulation documented in alprazolam withdrawal represents allostatic load — the neurobiological cost of maintaining apparent homeostasis through exogenous GABAergic augmentationsupported

Withdrawal produced CRF mRNA expression >300% increase in cerebral cortex, peaking 24-48h. Also HPA axis activation. pmid:15496666

What are the subtype-specific contributions to dependence? Confirmation in rhesus monkeys that GABA-A receptor subtypes make distinct contributions to alprazolam tolerance and dependence opens the question of which subtypes drive which components of human dependence formation.supported

Subtype-selective and non-selective ligands tested for cross-tolerance and withdrawal precipitation during chronic alprazolam treatment in rhesus monkeys. Subtype-specific contributions to tolerance and dependence confirmed. j.drugalcdep.2021.108985

Can subtype-selective modulators decouple anxiolysis from dependence? The observation that partial agonists do not produce tolerance suggests that reduced-efficacy ligands or α2/α3-selective modulators might provide anxiolysis without the neuroadaptive cascade driving dependence — a hypothesis actively pursued in preclinical research.supported

Partial agonist Ro16-6028 did NOT produce tolerance or receptor changes. pmid:1652596

Claim in neuroscience — inconclusiveinconclusiveworking →

The α5 subunit has been directly implicated in sedative tolerance development in knockout mouse models.supported

Alpha5-knock-in mice failed to develop sedative tolerance to diazepam. pmid:15282283

PET studies using radiolabeled alprazolam confirmed brain uptake at approximately 1% of administered dose, with distribution consistent with known benzodiazepine receptor density patternssupported

Brain uptake ~1% administered dose. Alprazolam acts as receptor binding ligand confirmed. pmid:7550022

Transcriptional repression: Sustained benzodiazepine stimulation induces α1 subunit gene downregulation via L-type voltage-gated calcium channel activation and downstream signaling cascades.supported

Diazepam exposure induces uncoupling of GABA/BZD sites and transcriptional downregulation of alpha1 GABA-A subunit via L-type calcium channels. Blocked by flumazenil, picrotoxin, or nifedipine. j.neulet.2020.134801

Epigenetic modification: HDAC1/2 upregulation mediates benzodiazepine-induced decrease in α1 subunit mRNA, introducing an epigenetic dimension to tolerance that may explain its persistence after drug cessation.supported

10-14 days diazepam treatment increased HDAC1 and HDAC2 in frontal cortex. prp2.416

Discontinuation of chronic alprazolam in dependent animals produces a dramatic upregulation of stress signaling: corticotropin-releasing factor (CRF) mRNA expression in the cerebral cortex increases by more than 300% within 24–48 hourssupported

Withdrawal produced CRF mRNA expression >300% increase in cerebral cortex, peaking 24-48h. pmid:15496666

Why does memory impairment resist tolerance? Tolerance develops to sedation and psychomotor impairment but not to short-term memory deficits. The subtype-specific mechanism — potentially involving α5-containing hippocampal receptors that undergo different neuroadaptive trajectories than α1-containing receptors — has not been resolved.supported

tolerance to psychomotor impairment but NOT to short-term memory impairment or reduced CFF. pmid:2871579

Does chronic therapeutic use cause lasting cognitive decline? Epidemiological studies suggest benzodiazepine use is associated with dementia risk, and animal data indicate hippocampal volume reduction, but causation has not been established.supported

Chronic BZD use may diminish hippocampal volume, impair neuroplasticity, and heighten dementia risk. s11033-026-11660-x

Does chronic therapeutic use cause lasting cognitive decline? Epidemiological studies suggest benzodiazepine use is associated with dementia risk, and animal data indicate hippocampal volume reduction, but causation has not been established.supported

Chronic diazepam impaired spatial learning in middle-aged but not young mice. Decreased LTP and dendritic spine density in hippocampal CA3. fnagi.2021.777404

Claim in pharmacology — inconclusiveinconclusiveworking →

Claim in pharmacology — inconclusiveinconclusiveworking →

The γ2 subunit is obligatory for benzodiazepine pharmacology; a Thr142Ser substitution in γ2 doubles alprazolam's potentiation efficacy, demonstrating that receptor architecture — not ligand structure alone — determines the magnitude of allosteric modulation.supported

gamma2 subunit Thr142Ser mutation doubles potentiation by alprazolam, diazepam, clonazepam. Efficacy determined by receptor structure, not just drug structure. pmid:7806498

Alprazolam is rapidly and nearly completely absorbed after oral administration, with absolute bioavailability of 80–100% and time to peak plasma concentration (Tmax) of 0.7–1.8 hourssupported

Typical PK after 1 mg oral: Cmax 12-22 mcg/L at 0.7-1.8h… Absolute bioavailability 80-100%. pmid:8513649

Pharmacokinetics are linear and dose-independent across the 2–10 mg range.supported

24 healthy male volunteers received sustained-release doses 2-10 mg. AUC and Cmax increased proportionally with dose (linear PK). pmid:9115058

Hepatic metabolism occurs primarily via CYP3A4, producing two active metabolites — α-hydroxyalprazolam and 4-hydroxyalprazolam — both present at less than 10% of parent drug concentrationspartially supported

Metabolites alpha-OH and 4-OH alprazolam <15% of parent concentration at all doses. pmid:9115058

The elimination half-life of 9–16 hours positions alprazolam as short-to-intermediate acting among benzodiazepines, with clearance of 0.7–1.5 mL/min/kg.supported

t1/2 9-16h, clearance 0.7-1.5 ml/min/kg. pmid:8513649

The relatively short half-life has direct clinical consequences: inter-dose withdrawal symptoms can emerge in dependent patients, and the rapid absorption rate of immediate-release formulations increases abuse liability compared to extended-release preparations.supported

Comparison of immediate-release vs extended-release alprazolam on reinforcing/subjective effects and abuse liability. pmid:7697954

Alprazolam (8-chloro-1-methyl-6-phenyl-4H-triazolo-benzodiazepine) is a high-potency triazolobenzodiazepine depressant and anxiolytic with an elimination half-life of 9–16 hours and oral bioavailability of 80–100%supported

Typical PK after 1 mg oral: t1/2 9-16h… Absolute bioavailability 80-100%. pmid:8513649

Among benzodiazepines, it occupies a distinctive position: short-to-intermediate acting, with rapid oral absorption (Tmax 0.7–1.8 hours) that contributes to both clinical efficacy and abuse liability.supported

Performance impaired at 1.25 and 2.5h, returned to baseline at 5.0h. Rapid IV onset (peak sedation 0.48h). pmid:6152055

Alprazolam acts as a non-selective full positive allosteric modulator at GABA-A receptors containing the γ2 subunit, with a Ki of 7.9 nM and EC50 of 56 nM for chloride current potentiation at α1β2γ2S receptorssupported

Alprazolam Ki at rat cortical membranes: 7.9 nmol/L. EC50 for potentiation of GABA-induced Cl- currents at alpha1beta2gamma2S GABA-A receptors: 56 nmol/L (98% maximum potentiation). pmid:10083975

Cryo-EM structural data reveal a halogen bond between the C8 chlorine and α1-His102 critical for receptor activation.supported

Cryo-EM structures of alprazolam bound GABA-A receptor (6HUO) investigated. Halogen bond between Cl of alprazolam and alpha1-His102 backbone identified as key binding interaction for PAM activity. j.bmcl.2022.128637

Alprazolam carries a wide therapeutic index in isolation — no fatalities from alprazolam alone are documented — but becomes acutely dangerous in combination with opioids or alcohol through pharmacodynamic synergismsupported

Pharmacodynamic synergism produces respiratory depression with opioids. 0897190013515001

Physical dependence develops within days of continuous use, driven by GABA-A receptor downregulation and α1 subunit transcriptional repressionpartially supported

After 18 days oral alprazolam in monkeys, flumazenil-precipitated withdrawal (tremor, vomiting, convulsions) occurred in all treated animals. pmid:7617819

Physical dependence develops within days of continuous use, driven by GABA-A receptor downregulation and α1 subunit transcriptional repressionsupported

BZD agonists lorazepam, alprazolam, clonazepam produced tolerance associated with GABA-A receptor downregulation… Gene expression for GABA-A subunits changed with chronic lorazepam. pmid:1652596

Tolerance to sedation develops faster than tolerance to memory impairment, which persists with chronic usesupported

43 long-term BZD users (avg 5 years): tolerance to psychomotor impairment but NOT to short-term memory impairment or reduced CFF. pmid:2871579

Panic-free rates were maintained during treatment, but one-third of patients were unable to discontinue during a 3-week taper protocol, underscoring the dependence liability inherent to sustained use.supported

8-month double-blind trial: 62% of alprazolam patients panic-free vs 26% imipramine/placebo. One-third could not discontinue during 3-week taper. pmid:9872708

Alprazolam demonstrates efficacy for short-term management of generalized anxiety, though guidelines generally favor SSRIs, SNRIs, or buspirone as first-line agents due to dependence concernssupported

GAD treatment review: benzodiazepines including alprazolam XR have best evidence. Physical dependence risk. SSRIs/venlafaxine/paroxetine/sertraline efficacious without dependence. pmid:12562113

A meta-analysis comparing alprazolam to other benzodiazepines for panic disorder found comparable efficacy across the class, with no clear superiority of alprazolam over clonazepam or diazepam for panic-free rates.supported

Meta-analysis of 8 RCTs (631 patients). No significant difference in efficacy between alprazolam and other BZDs on panic attack frequency, Hamilton Anxiety, or panic-free proportion. jcp.0b013e31822d0012

Anxiety symptom reduction occurs within the first week of treatment.supported

fast onset (within 1 week). pmid:14978513

Results supported efficacy for alprazolam in this indication, though diazepam remains the standard of care due to its longer half-life and self-tapering pharmacokinetics.partially supported

Alprazolam significantly more efficacious than clonidine and placebo in decreasing alcohol withdrawal symptoms. pmid:7978098

A case series documented successful management of alprazolam withdrawal using chlordiazepoxide substitution at approximately 86:1 ratio (chlordiazepoxide mg to alprazolam mg), followed by gradual tapersupported

First case series (n=6) of chlordiazepoxide substitution for alprazolam withdrawal. Mean substitution ratio 86:1 (chlordiazepoxide:alprazolam mg). 7-14 day taper at 10%/day. No seizures. pmid:7966502

Meta-analytic evidence indicates no significant difference in efficacy between alprazolam and other benzodiazepines for panic disordersupported

No significant difference in efficacy between alprazolam and other BZDs on panic attack frequency, Hamilton Anxiety, or panic-free proportion. jcp.0b013e31822d0012

Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

Worsening of PTSD symptoms, increased impulsivity in borderline personality disorder, and induction of mania or hypomania are reported more frequently with alprazolam than with older benzodiazepinessupported

Unique alprazolam findings: worsening PTSD, increased impulsivity in borderline personality disorder, mania/hypomania. Older BZDs more commonly reported for other events. pmid:8262890

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

The C8 chlorine of alprazolam forms a halogen bond with the backbone nitrogen of α1-His102, a contact critical for PAM activitysupported

Halogen bond between Cl of alprazolam and alpha1-His102 backbone identified as key binding interaction for PAM activity. j.bmcl.2022.128637

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

Key functional groups include a chlorine substituent at position 8 of the benzodiazepine ring (contributing to receptor binding via halogen bonding with α1-His102), a methyl group at position 1 of the triazole ring, and a phenyl ring at position 6.supported

Halogen bond between Cl of alprazolam and alpha1-His102 backbone identified as key binding interaction for PAM activity. j.bmcl.2022.128637

Claim in effects-overview — inconclusiveinconclusiveworking →

Generic alprazolam became available after the patent's 1993 expiration, and the compound has since become one of the most widely prescribed and most frequently misused benzodiazepines worldwide.partially supported

Alprazolam is one of the most misused BZDs in France. j.therap.2023.02.002

Claim in legal-status — inconclusiveinconclusiveworking →